Amyotrophic lateral sclerosis research appropriation provision and appropriation cancellation provision
Summary
SF3155 revises Minnesota’s existing state funding structure for amyotrophic lateral sclerosis (ALS) research. The bill cancels $15 million from a prior appropriation to the Office of Higher Education and instead reappropriates that same amount in fiscal year 2026 to the University of Minnesota Board of Regents for a collaborative research partnership with the Mayo Clinic. The stated purpose is to support ongoing ALS research aimed at improving the lives of people with ALS and finding a cure.
The bill also requires the University of Minnesota to report annually to the legislature beginning January 15, 2026, through January 15, 2030, or until the money is spent. Those reports must describe how the funds were used by the partnership. In addition, the bill repeals the prior ALS research appropriation law, as amended in 2024, thereby replacing the earlier grant-based structure with a more direct university-led research appropriation.
Impact
The bill changes state law by canceling and repealing a prior ALS research appropriation administered through the Office of Higher Education and replacing it with a one-time $15 million appropriation to the University of Minnesota for a specific partnership with Mayo Clinic. It shifts the funding mechanism away from competitive grants to Minnesota research entities and toward a targeted institutional collaboration, while extending the availability of unencumbered funds until June 30, 2029. The bill also imposes legislative reporting requirements on the Board of Regents, creating ongoing oversight of how the funds are spent and what results are produced.
Sentiment
Based on the bill text and available context, the measure appears generally supportive and noncontroversial in purpose, as it continues state investment in ALS research and frames the funding as a way to improve patient outcomes and pursue a cure. The authorship by a bipartisan group of senators also suggests broad interest in the issue. No committee testimony or recorded votes were provided, so there is no evidence in the available record of organized opposition or divided sentiment.
Contention
The main policy issue is not whether to fund ALS research, but how to structure that funding. The bill replaces a broader competitive grant program administered through the Office of Higher Education with a single collaborative partnership involving the University of Minnesota and Mayo Clinic. That shift could raise questions about concentration of funds, the loss of competitive grant opportunities for other Minnesota research institutions, and whether the new structure is more effective than the prior model. The bill also cancels an existing appropriation, which may be a point of concern for parties expecting the original grant program to continue.